![[logo] HealthTree Foundation](https://static.healthtree.org/icons/icon_spinner.svg){kind=icon}
![[logo] HealthTree Foundation](https://static.healthtree.org/logo_icon_only.svg){kind=icon}
Reducing Relapse Risk After Transplant Using Jakafi With Gabriela Hobbs, MD, Massachusetts General Hospital
Reducing Relapse Risk After Transplant Using Jakafi With Gabriela Hobbs, MD, Massachusetts General Hospital
Event Description
IF YOU WOULD PREFER TO JOIN THE SHOW BY PHONE, PLEASE CALL (515) 602-9728.
*You need to join by phone if you want to ask Dr. Hobbs your questions.*
Allogeneic stem cell transplantation is the only curative option for patients battling acute myeloid leukemia. However, a significant number of patients will relapse after transplant. Innovative research and therapies are needed in order to improve outcomes in AML patients.
The drug Jakafi (ruxolitinib), a kinase inhibitor, is being explored in a current clinical trial as it may help reduce the risk of relapse. Other therapies such as pre-emptive donor lymphocyte infusions, hypomethylating agents and FLT3 inhibitors combined with donor lymphocyte infusions, CAR T-cell and CAR-NK cells are some of the relapse prevention treatment strategies being explored.
Join us live on Wednesday, October 5th at 1:30 pm EST to hear from Dr. Gabriela Hobbs with Massachusetts General Hospital who will be discussing her clinical trial using Jakafi (ruxolitinib) after allogeneic stem cell transplant as well as other therapies to reduce relapse risk. There will be time at the end of the show to ask Dr. Hobbs your questions directly!
Thank you to our episode sponsor, Bristol Myers Squibb.
Schedule & Agenda
Speakers & Moderators
Dr. Gabriela Hobbs ia a hematology-oncology physician who specializes in the care of patients with myeloproliferative neoplasms (MPN), chronic myeloid leukemia and leukemia. She is an active clinical researcher, leads the MPN research program at Massachusetts General Hospital and also participates in translational research for MPN. In addition, Dr. Hobbs is the clinical director for the adult leukemia service at MGH.
Kerith joined HealthTree Foundation as a Community Co-Director for AML in 2022. She is a mother to a spirited eight-year-old daughter, Adair, and their beloved rescue, Violet. She lost her best friend and husband, Rob, to AML in March 2018. Kerith wishes she had a resource such as HealthTree for AML during Rob’s illness. She is a strong supporter of HealthTree's mission. She hopes that by sharing her experience, she may help other patients and caregivers navigate an AML diagnosis.
Have Any Questions?
Thank you for your interest in the event. If you have any questions, we would love to help!
Feel free to give us a call or send us a message below.
Get In Touch With Us
1-800-709-1113
Support@healthtree.org
Your Source for Expert Insights & Support in Blood Cancer.
By subscribing to the Healthtree newsletter, you'll receive the latest research, treatment updates, and expert insights to help you navigate your health.
HealthTree Foundation is a qualified 501(c)(3) tax-exempt organization.
Copyright © 2025 HealthTree Foundation. All rights reserved.
Tax ID 45-5354811